# Aldea Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aldea-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Palo Alto, US
- Website: www.aldeapharma.com
- Total disclosed funding: $11M
- Latest round: Series B (Aug 21, 2014)
- Investors on record: 5

## About

Aldea Pharmaceuticals is a biotechnology firm focused on developing innovative therapies for treating complex diseases. The company specializes in advancing drug discovery and clinical development to address significant unmet medical needs.Aldea Pharmaceuticals, founded in 2011 and headquartered in Palo Alto, US, is dedicated to advancing drug therapies. The company has undergone strategic pivots since its inception, ensuring a robust approach towards drug development. The latest funding round was a Series B, which raised USD 9.26 mn on August 21, 2014, from prominent investors including 6 Dimensions Capital and Canaan Partners. Aldea has secured a total of USD 9.26 mn in funding to date and has been involved in five different deals.Aldea Pharmaceuticals focuses on developing therapeutic solutions targeting severe and complex medical conditions. Their research and product pipeline includes a range of potential treatments that aim to address significant health challenges faced by patients, emphasizing innovative approaches within the biotechnology sector.Aldea Pharmaceuticals generates revenue through strategic partnerships and licensing agreements for its therapeutic candidates as they progress through clinical development stages. The company emphasizes its commitment to bringing its therapies to market effectively, ensuring that they meet regulatory standards and fulfill market needs.Aldea Pharmaceuticals plans to leverage the recent Series B funding of USD 9.26 mn to further its research and development efforts. The company aims to expand its product pipeline with new treatments set to enter clinical trials within the next two years. Additionally, Aldea is exploring opportunities for market expansion into Europe and Asia by 2016, focusing on regions with high demand for innovative therapies. This strategic approach is designed to ensure the company’s growth as it continues to develop solutions for unmet medical needs.

## Funding rounds

- Series B, Aug 21, 2014, $9.3M — Canaan Partners, Correlation Ventures, Rosnano, 6 Dimensions Capital, RMI Partners
- Seed, Apr 1, 2013, $2M — Canaan Partners

## Investors

- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Seed, Series B
- Correlation Ventures (https://capitalatlas.ai/funds/correlation-ventures) — Series B
- Rosnano — Series B
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series B
- RMI Partners (https://capitalatlas.ai/funds/rmi-partners) — Series B